D'Souza DC - Search Results

1

The safety of studies with intravenous Δ⁹-tetrahydrocannabinol in humans, with case histories.

Carbuto M, Sewell RA, Williams A, Forselius-Bielen K, Braley G, Elander J, Pittman B, Schnakenberg A, Bhakta S, Perry E, Ranganathan M, D'Souza DC; Yale THC Study Group. Carbuto M, et al. Psychopharmacology (Berl). 2012 Feb;219(3):885-96. doi: 10.1007/s00213-011-2417-y. Epub 2011 Aug 16. Psychopharmacology (Berl). 2012. PMID: 21845389

2

Precipitation of a psychoneuromotor syndrome by fluoxetine in a haloperidol-treated schizophrenic patient.

D'Souza DC, Bennett A, Abi-Dargham A, Krystal JH. D'Souza DC, et al. J Clin Psychopharmacol. 1994 Oct;14(5):361-3. J Clin Psychopharmacol. 1994. PMID: 7806697 No abstract available.

3

Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans.

Krystal JH, Karper LP, Bennett A, D'Souza DC, Abi-Dargham A, Morrissey K, Abi-Saab D, Bremner JD, Bowers MB Jr, Suckow RF, Stetson P, Heninger GR, Charney DS. Krystal JH, et al. Psychopharmacology (Berl). 1998 Feb;135(3):213-29. doi: 10.1007/s002130050503. Psychopharmacology (Berl). 1998. PMID: 9498724 Free article. Clinical Trial.

4

The NMDA antagonist model for schizophrenia: promise and pitfalls.

Abi-Saab WM, D'Souza DC, Moghaddam B, Krystal JH. Abi-Saab WM, et al. Pharmacopsychiatry. 1998 Jul;31 Suppl 2:104-9. doi: 10.1055/s-2007-979354. Pharmacopsychiatry. 1998. PMID: 9754841 Review.

5

D-serine and the therapeutic challenge posed by the N-methyl-D-aspartate antagonist model of schizophrenia.

Krystal JH, D'Souza DC. Krystal JH, et al. Biol Psychiatry. 1998 Dec 1;44(11):1075-6. doi: 10.1016/s0006-3223(98)00284-4. Biol Psychiatry. 1998. PMID: 9836009 Free article. No abstract available.

6

Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients.

Krystal JH, D'Souza DC, Madonick S, Petrakis IL. Krystal JH, et al. Schizophr Res. 1999 Mar 1;35 Suppl:S35-49. doi: 10.1016/s0920-9964(98)00162-5. Schizophr Res. 1999. PMID: 10190224 Free article. Review.

7

Interactive effects of subanesthetic ketamine and haloperidol in healthy humans.

Krystal JH, D'Souza DC, Karper LP, Bennett A, Abi-Dargham A, Abi-Saab D, Cassello K, Bowers MB Jr, Vegso S, Heninger GR, Charney DS. Krystal JH, et al. Psychopharmacology (Berl). 1999 Jul;145(2):193-204. doi: 10.1007/s002130051049. Psychopharmacology (Berl). 1999. PMID: 10463321 Clinical Trial.

8

NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders.

Krystal JH, D'Souza DC, Petrakis IL, Belger A, Berman RM, Charney DS, Abi-Saab W, Madonick S. Krystal JH, et al. Harv Rev Psychiatry. 1999 Sep-Oct;7(3):125-43. Harv Rev Psychiatry. 1999. PMID: 10483932 Review.

9

Symptom provocation studies in psychiatric disorders: scientific value, risks, and future.

D'Souza DC, Berman RM, Krystal JH, Charney DS. D'Souza DC, et al. Biol Psychiatry. 1999 Oct 15;46(8):1060-80. doi: 10.1016/s0006-3223(99)00209-7. Biol Psychiatry. 1999. PMID: 10536743 Review.

10

Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions.

Krystal JH, Bennett A, Abi-Saab D, Belger A, Karper LP, D'Souza DC, Lipschitz D, Abi-Dargham A, Charney DS. Krystal JH, et al. Biol Psychiatry. 2000 Jan 15;47(2):137-43. doi: 10.1016/s0006-3223(99)00097-9. Biol Psychiatry. 2000. PMID: 10664830 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

184 results

Search Page

Filters